Email updates

Keep up to date with the latest news and content from BMC Cancer and BioMed Central.

Open Access Highly Accessed Research article

Genetically engineered endostatin-lidamycin fusion proteins effectively inhibit tumor growth and metastasis

Wen-guo Jiang12, Xin-an Lu34, Bo-yang Shang1, Yan Fu34, Sheng-hua Zhang1, Daifu Zhou4, Liang Li1, Yi Li1, Yongzhang Luo34* and Yong-su Zhen1*

Author Affiliations

1 Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, P. R. China

2 Department of Pharmacology, Binzhou Medical University, Yantai, Shandong 264003, P. R. China

3 Beijing Key Laboratory of Protein Therapeutics, Department of Biological Sciences and Biotechnology, Tsinghua University, Beijing 100084, P. R. China

4 National Engineering Laboratory for Anti-tumor Protein Therapeutics, Tsinghua University, Beijing 100084, P. R. China

For all author emails, please log on.

BMC Cancer 2013, 13:479  doi:10.1186/1471-2407-13-479

Published: 15 October 2013

Abstract

Background

Endostatin (ES) inhibits endothelial cell proliferation, migration, invasion, and tube formation. It also shows antiangiogenesis and antitumor activities in several animal models. Endostatin specifically targets tumor vasculature to block tumor growth. Lidamycin (LDM), which consists of an active enediyne chromophore (AE) and a non-covalently bound apo-protein (LDP), is a member of chromoprotein family of antitumor antibiotics with extremely potent cytotoxicity to cancer cells. Therefore, we reasoned that endostatin-lidamycin (ES-LDM) fusion proteins upon energizing with enediyne chromophore may obtain the combined capability targeting tumor vasculature and tumor cell by respective ES and LDM moiety.

Methods

In this study, we designed and obtained two new endostatin-based fusion proteins, endostatin-LDP (ES-LDP) and LDP-endostatin (LDP-ES). In vitro, the antiangiogenic effect of fusion proteins was determined by the wound healing assay and tube formation assay and the cytotoxicity of their enediyne-energized analogs was evaluated by CCK-8 assay. Tissue microarray was used to analyze the binding affinity of LDP, ES or ES-LDP with specimens of human lung tissue and lung tumor. The in vivo efficacy of the fusion proteins was evaluated with human lung carcinoma PG-BE1 xenograft and the experimental metastasis model of 4T1-luc breast cancer.

Results

ES-LDP and LDP-ES disrupted the formation of endothelial tube structures and inhibited endothelial cell migration. Evidently, ES-LDP accumulated in the tumor and suppressed tumor growth and metastasis. ES-LDP and ES show higher binding capability than LDP to lung carcinoma; in addition, ES-LDP and ES share similar binding capability. Furthermore, the enediyne-energized fusion protein ES-LDP-AE demonstrated significant efficacy against lung carcinoma xenograft in athymic mice.

Conclusions

The ES-based fusion protein therapy provides some fundamental information for further drug development. Targeting both tumor vasculature and tumor cells by endostatin-based fusion proteins and their enediyne-energized analogs probably provides a promising modality in cancer therapy.

Keywords:
Endostatin; Lidamycin; Fusion protein; Antiangiogenesis